Cargando…

Knockdown of lactate dehydrogenase by adeno‐associated virus‐delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1

BACKGROUND: Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder caused by endogenous overproduction of hepatic oxalate, leading to hyperoxaluria, recurrent calcium oxalate kidney stones, and end‐stage renal disease. Lactate dehydrogenase (LDH) is an ideal target for diminishing oxalate pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Rui, Fang, Xiaoliang, Chen, Xi, Huang, Yunteng, Xu, Guofeng, He, Lei, Li, Yueyan, Niu, Xuran, Yang, Lei, Wang, Liren, Li, Dali, Geng, Hongquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752156/ https://www.ncbi.nlm.nih.gov/pubmed/33377632 http://dx.doi.org/10.1002/ctm2.261

Ejemplares similares

In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
por: Martinez-Turrillas, Rebeca, et al.
Publicado: (2022)

Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria
por: Lai, Chengjung, et al.
Publicado: (2018)

Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice
por: Yu, Wenhan, et al.
Publicado: (2017)

Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria
por: Ariceta, Gema, et al.
Publicado: (2021)

Adeno-Associated Vector-Delivered CRISPR/SaCas9 System Reduces Feline Leukemia Virus Production In Vitro
por: Helfer-Hungerbuehler, A. Katrin, et al.
Publicado: (2021)

Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus
por: Kim, Do Yon, et al.
Publicado: (2021)

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I
por: Zabaleta, Nerea, et al.
Publicado: (2018)

CRISPR/Cas13d-Mediated Microbial RNA Knockdown
por: Zhang, Kun, et al.
Publicado: (2020)

Targeted gene knockdown validates the essential role of lactate dehydrogenase in Cryptosporidium parvum
por: Witola, William H., et al.
Publicado: (2017)

Development of an Agrobacterium‐delivered CRISPR/Cas9 system for wheat genome editing
por: Zhang, Zhengzhi, et al.
Publicado: (2019)

Lactate Dehydrogenase A or B Knockdown Reduces Lactate Production and Inhibits Breast Cancer Cell Motility in vitro
por: Khajah, Maitham A., et al.
Publicado: (2021)

The CRISPR/Cas9 System Delivered by Extracellular Vesicles
por: Zhu, Xinglong, et al.
Publicado: (2023)

Specific knockdown of Htra2 by CRISPR-CasRx prevents acquired sensorineural hearing loss in mice
por: Guo, Yang, et al.
Publicado: (2022)

Primary Hyperoxaluria
por: Harambat, Jérôme, et al.
Publicado: (2011)

Targeted RNA Knockdown by a Type III CRISPR-Cas Complex in Zebrafish
por: Fricke, Thomas, et al.
Publicado: (2020)

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
por: Zhang, Song, et al.
Publicado: (2021)

Co-editing PINK1 and DJ-1 Genes Via Adeno-Associated Virus-Delivered CRISPR/Cas9 System in Adult Monkey Brain Elicits Classical Parkinsonian Phenotype
por: Li, Hao, et al.
Publicado: (2021)

HIV-1 mRNA Knockdown with CRISPR/Cas9 Enhances Neurocognitive Function
por: McLaurin, Kristen A, et al.
Publicado: (2023)

An Agrobacterium‐delivered CRISPR/Cas9 system for targeted mutagenesis in sorghum
por: Char, Si Nian, et al.
Publicado: (2019)

Intra-embryo Gene Cassette Knockin by CRISPR/Cas9-Mediated Genome Editing with Adeno-Associated Viral Vector
por: Mizuno, Naoaki, et al.
Publicado: (2018)

Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium
por: Metry, Elisabeth L., et al.
Publicado: (2023)

Signal Amplification by the trans-Cleavage Activity of CRISPR-Cas Systems: Kinetics and Performance
por: Feng, Wei, et al.
Publicado: (2023)

Multiplexed CRISPR-Cas9 system in a single adeno-associated virus to simultaneously knock out redundant clock genes
por: Kim, Boil, et al.
Publicado: (2021)

Exosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs
por: Lin, Yao, et al.
Publicado: (2018)

The present and potential future methods for delivering CRISPR/Cas9 components in plants
por: Sandhya, Dulam, et al.
Publicado: (2020)

Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma
por: Liu, Xiao, et al.
Publicado: (2023)

Primary hyperoxaluria and systemic oxalosis
por: Sriram, K., et al.
Publicado: (2007)

Enteric hyperoxaluria in chronic pancreatitis
por: Demoulin, Nathalie, et al.
Publicado: (2017)

An Agrobacterium‐delivered CRISPR/Cas9 system for high‐frequency targeted mutagenesis in maize
por: Char, Si Nian, et al.
Publicado: (2016)

In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials
por: Selle, Kurt, et al.
Publicado: (2020)

Lactate Dehydrogenase-Elevating Virus
por: Coutelier, Jean-Paul, et al.
Publicado: (2007)

Lactate Dehydrogenase: The Beacon of Hope?
por: Pandarathodiyil, Anitha Krishnan, et al.
Publicado: (2022)

Lactate Conversion by Lactate Dehydrogenase B Is Involved in Beige Adipocyte Differentiation and Thermogenesis in Mice
por: Guo, Bin, et al.
Publicado: (2023)

Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases
por: Han, Jung Ho, et al.
Publicado: (2023)

CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis
por: Simbulan-Rosenthal, Cynthia M., et al.
Publicado: (2019)

CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown
por: Zhao, Nannan, et al.
Publicado: (2023)

Pancytopenia as a Complication of Primary Hyperoxaluria
por: Khosravi, M., et al.
Publicado: (2019)

The Struggling Odyssey of Infantile Primary Hyperoxaluria
por: Guillaume, Adrien, et al.
Publicado: (2021)

Treatment of primary hyperoxaluria type 1
por: Gupta, Asheeta, et al.
Publicado: (2022)

Improving Treatment Options for Primary Hyperoxaluria
por: Hoppe, Bernd, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h2ssdvvoe26qjtpv5fjb2qqlek